1-4 of 4
Min Jung Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent

Finith Jernigan, Arthur Branstrom, John D. Baird, Liangxian Cao, Mandar Dali, Bansri Furia, Min Jung Kim, Kylie O'Keefe, Ronald Kong, Oscar L. Laskin, Joseph M. Colacino, Mark Pykett, Anna Mollin, Josephine Sheedy, Melissa Dumble, Young-Choon Moon, Richard Sheridan, Tobias Mühlethaler, Robert J. Spiegel, Andrea E. Prota, Michel O. Steinmetz, Marla Weetall
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1846–1857.
https://doi.org/10.1158/1535-7163.MCT-20-0774
Published: 01 October 2021
View article titled, Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
Open the PDF for Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent in another window
Journal Articles

Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies

Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim, Dae Seog Heo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (3): 937–944.
https://doi.org/10.1158/1535-7163.MCT-19-0457
Published: 02 March 2020
View article titled, Clinical Application of Next-Generation Sequencing–Based Panel to <em>BRAF</em> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
Open the PDF for Clinical Application of Next-Generation Sequencing–Based Panel to <em>BRAF</em> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies in another window
Includes: Supplementary data
Journal Articles

Inhibition of Y Box Binding Protein 1 Suppresses Cell Growth and Motility in Colorectal Cancer

Areumnuri Kim, Sehwan Shim, Young-heon Kim, Min-Jung Kim, Sunhoo Park, Jae Kyung Myung
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (2): 479–489.
https://doi.org/10.1158/1535-7163.MCT-19-0265
Published: 06 February 2020
View article titled, Inhibition of Y Box Binding Protein 1 Suppresses Cell Growth and Motility in Colorectal Cancer
Open the PDF for Inhibition of Y Box Binding Protein 1 Suppresses Cell Growth and Motility in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

Liangxian Cao, Marla Weetall, Christopher Trotta, Katherine Cintron, Jiyuan Ma, Min Jung Kim, Bansri Furia, Charles Romfo, Jason D. Graci, Wencheng Li, Joshua Du, Josephine Sheedy, Jean Hedrick, Nicole Risher, Shirley Yeh, Hongyan Qi, Tamil Arasu, Seongwoo Hwang, William Lennox, Ronald Kong, Janet Petruska, Young-Choon Moon, John Babiak, Thomas W. Davis, Allan Jacobson, Neil G. Almstead, Art Branstrom, Joseph M. Colacino, Stuart W. Peltz
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (1): 3–16.
https://doi.org/10.1158/1535-7163.MCT-18-0863
Published: 02 January 2019
View article titled, Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Open the PDF for Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties in another window
Includes: Supplementary data